

FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2022
FOR
J. K. V. PHARMA LIMITED

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2022**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4
Report of the Accountants	6

J. K. V. PHARMA LIMITED
COMPANY INFORMATION
FOR THE YEAR ENDED 30 NOVEMBER 2022

DIRECTOR: J K Vekaria

REGISTERED OFFICE: 248 Church Lane
London
NW9 8SL

REGISTERED NUMBER: 09316632

ACCOUNTANTS: Gill & Company
248 Church Lane
Kingsbury
London
NW9 8SL

BALANCE SHEET
30 NOVEMBER 2022

	Notes	2022 £	£	2021 £	£
FIXED ASSETS					
Tangible assets	4		364		485
Investments	5		<u>100,000</u>		<u>100,000</u>
			100,364		100,485
CURRENT ASSETS					
Prepayments and accrued income		223		217	
Cash at bank		<u>164,021</u>		<u>99,447</u>	
		164,244		99,664	
CREDITORS					
Amounts falling due within one year	6	<u>31,180</u>		<u>19,989</u>	
NET CURRENT ASSETS			<u>133,064</u>		<u>79,675</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>233,428</u>		<u>180,160</u>
RESERVES					
Retained earnings			<u>233,428</u>		<u>180,160</u>
SHAREHOLDERS' FUNDS			<u>233,428</u>		<u>180,160</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2022 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

BALANCE SHEET - continued
30 NOVEMBER 2022

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 May 2023 and were signed by:

J K Vekaria - Director

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2022**

1. STATUTORY INFORMATION

J. K. V. Pharma Limited is a private company, limited by shares, registered in Not specified/Other. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents the net invoiced fees received, excluding VAT.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2021 - 1).

4. TANGIBLE FIXED ASSETS

	Plant and machinery etc £
COST	
At 1 December 2021	
and 30 November 2022	<u>3,448</u>
DEPRECIATION	
At 1 December 2021	2,963
Charge for year	<u>121</u>
At 30 November 2022	<u>3,084</u>
NET BOOK VALUE	
At 30 November 2022	<u><u>364</u></u>
At 30 November 2021	<u><u>485</u></u>

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2022**

5. FIXED ASSET INVESTMENTS

Investments (neither listed nor unlisted) were as follows:

	2022	2021
	£	£
Other investment	<u>100,000</u>	<u>100,000</u>

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022	2021
	£	£
Trade creditors	1,320	-
Taxation and social security	28,331	17,946
Other creditors	<u>1,529</u>	<u>2,043</u>
	<u>31,180</u>	<u>19,989</u>

J. K. V. PHARMA LIMITED

**REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF
J. K. V. PHARMA LIMITED**

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 30 November 2022 set out on pages three to seven and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.

Gill & Company
248 Church Lane
Kingsbury
London
NW9 8SL

30 May 2023

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.